Loading
Led ARCHES, which established enzalutamide with hormone therapy for metastatic hormone-sensitive prostate cancer.
Andrew Armstrong was principal investigator of ARCHES, the trial showing enzalutamide plus androgen deprivation improves radiographic progression-free and overall survival in metastatic hormone-sensitive prostate cancer, and led the PROPHECY study validating AR-V7 in circulating tumour cells as a marker of resistance to AR inhibitors. He directs prostate cancer research at Duke.
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Androgen deprivation & AR pathway inhibitors, Androgen receptor, Prostate cancer and the tags prostate, trialist.
Shares Androgen receptor, Liquid biopsy (ctDNA), Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.
Shares Prostate cancer and the tags prostate, trialist.